Research

Research Theme

The Project Leader's Profile

Yoshinao Wada

Invited Professor; Director of the Research Institute, Osaka Medical Center and Research Institute for Maternal and Child Health.

In 1975, graduated from Osaka University School of Medicine. After working as an internist in a city hospital, in 1981 moved to the Osaka Medical Center and Research Institute for Maternal and Child Health (MCHRI). In 1981, developed a basic method of analyzing mutated proteins by mass spectrometry.  In 1992, delineated the molecular features of glycoproteins specific to Congenital Disorders of Glycosylation (CDG). From 1998, he holds the current position. Specialized in biological mass spectrometry. He is serving for International Mass Spectrometry Foundation as the representative of Region B (Asia), and for Japan Mass Spectrometry Society as the President.

Project Leader
  • Yoshinao Wada, M.D., Ph.D., Invited Professor, Director of the Research Institute, Osaka Medical Center and Research Institute for Maternal and Child Health
Research Members
  • Yukinao Shibukawa, Senior Scientist, Department of Molecular Medicine, Research Institute, Osaka Medical Center for Maternal and Child Health
Research Collaborators
  • Michiko Tajiri, Scientist, Japan Science and Technology Agency
  • Nobuhiko Okamoto, Pediatrician, Department of Medical Intelligence and Planning, Osaka Medical Center for Maternal and Child Health

Summary

Following development of the method of structure elucidation of protein mutations and posttranslational modifications by mass spectrometry in 1981, the basic strategy with subsequent technologies has been applied to the study of molecular pathology of diseases. In the current project, mass spectrometry is focused on glycoproteomics, in which technical problems in the structural analysis of O-glycosylation will be solved and thereby glycan biomarkers will be explored in various diseases. On the other hand, a fieldwork for the diagnosis of Congenital Disorders of Glycosylation, CDG, is conducted in order to unravel the frequency of this syndrome. These studies will broaden our horizons of clinical glycoproteomics.

wada.jpg So far identified defects in the Congenital Disorders of Glycosylation (CDG), and our diagnostic strategy.

Some of Recent Papers

  1. Tajiri M, Kadoya M, Wada Y. Dissociation profile of protonated fucosyl glycopeptides and quantitation of fucosylation levels of glycoproteins by mass spectrometry. J Proteome Res. 2008 Dec 19. [Epub ahead of print]
  2. Tajiri M, Ohyama C, Wada Y. Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from prostate cancer patient serum and in seminal plasma: a glycopeptide approach. Glycobiology. 18, 2-8, 2008
  3. Wada Y, Yanagishita T, Masuda H. Ordered porous alumina geometries and surface metals for surface-assisted laser desorption/ionization of biomolecules: Possible mechanistic implications of metal surface melting. Anal Chem 79, 9122-9127 (2007)
  4. Wada Y, et al. Comparison of the methods for profiling glycoprotein glycans - HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study. Glycobiology 17: 411-422 (2007)